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Abstract
Background: Liposarcoma is the most frequent histopathological variety of the retroperitoneum,
surgery is the gold standard for treatment.
Case presentation: We present the case of a 24-year-old male who was diagnosed with a giant
retroperitoneal liposarcoma. The patient received palliative treatment due to non-resectability on
the basis of chemotherapy. We decided to perform surgery after no benefit was received with
systemic treatment. Complete macroscopic resection of the tumor was performed, without multi-
organ resection. The patient is currently alive and disease free at 14 months of evolution.
Conclusion:  Retroperitoneal liposarcomas represent a unique situation and require a more
aggressive surgical approach including multiple resections for recurrences. Based on the ability of
the patient to tolerate the procedure, surgery is suggested to evaluate resectability of the tumor.
We must take into consideration whether prolonged survival will be attained and tumor removal
will result in palliation of symptoms.
Background
Liposarcomas are neoplasms of mesodermic origin
derived from adipose tissue and correspond to 10–14% of
all soft tissue sarcomas. They represent < 1% of all malig-
nant tumors [1,2].
The most frequent subtypes are liposarcoma (41%), leio-
myosarcoma (28%), malignant fibrous histiocytoma
(7%), fibrosarcoma (6%) and tumors of the peripheral
nerve sheath (3%) [3]. Retroperitoneal liposarcomas
alone comprise 0.07–0.2% of all neoplasias4. Approxi-
mately 85% of these are malignant, with soft-tissue sarco-
mas representing 35% of this group. Liposarcoma is the
most frequent histopathological variety of the retroperito-
neum [2]. It presents with inherent characteristics in rela-
tion to its deep localization and slow expansive growth.
Average diameter of the tumor is 20–25 cm with a weight
of 15–20 kg [4]. There is compromise of the adjacent
organs in up to 80% of the cases [4,5]. Surgery is the gold
standard for treatment of liposarcoma. Retroperitoneal
liposarcoma is a distinct clinical entity that requires a
more aggressive surgical approach, including multiple
resections or multiorgan resection with recurrences. There
is a low incidence of distance metastasis (7%) compared
to other histological subtypes that range from 15 to 34%
[6]. The objective of this study is to report a case of giant
retroperitoneal sarcoma.
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Case presentation
A 24-year-old male presented with a 6-month evolution
of his disease with abdominal pain, constipation, fever
and a 20-kg weight loss. He received treatment for typhoid
fever without improvement. For this reason, abdominal
tomography was performed, demonstrating a heterogene-
ous lesion with zones of fat and solid density that entirely
occupied the abdominal cavity, displacing retroperitoneal
structures dorsally. CT-guided biopsy was performed at a
different hospital and pathological report demonstrated
liposarcoma. Colonoscopy was performed, demonstrat-
ing extrinsic compression at the level of the descending
colon. The patient was sent to our Institution for further
evaluation. Upon admission, the patient had a Karnofsky
score of 90 and was classified as grade zero according to
the status of the Eastern Cooperative Oncology Group
(ECOG). He also presented with respiratory difficulty and
distended abdomen due to solid, multilobulated tumor
that extended from the epigastrium to the pelvic region
without delineated borders. CT scan confirmed previous
findings (Fig. 1). Histopathological review from the refer-
ring hospital demonstrated minute fragments of mature
adipose tissue without atypia. This material was consid-
ered to be inadequate for diagnosis. For this reason, a new
CT-guided biopsy was performed and a well-differenti-
ated sclerosing-type liposarcoma was reported (Fig. 2).
CT scan Figure 1
CT scan. Heterogeneous lesion is observed with zones of fat and solid density that entirely occupy the abdominal cavity, dis-
placing retroperitoneal structures dorsally.World Journal of Surgical Oncology 2008, 6:115 http://www.wjso.com/content/6/1/115
Page 3 of 6
(page number not for citation purposes)
Because the patient's tumor had previously been consid-
ered nonresectable, he was referred to medical oncology
where chemotherapy with ifosfamide and adriamycin was
offered. Clinical and radiological responses were evalu-
ated and reported stable disease. The patient completed
six cycles of adriamycin and ifosfamide and was re-evalu-
ated upon treatment completion. The patient continued
with stable disease (no change in tumor size was docu-
mented either clinically or radiologically) without change
in functional status according to Karnofsky index upon
admission. At the conclusion of chemotherapy, support-
ive therapy vs. chemotherapy with etoposide and ifosfa-
mide was proposed and the patient elected supportive
therapy. An interdepartmental meeting was held and, in a
joint decision with the patient, surgical exploration was
decided upon. Surgery was performed with the patient in
dorsal decubitus and a midline incision was made from
the xyphoid to the pubis, revealing an 80 × 60-cm tumor
that encompassed the entire retroperitoneal cavity, with
lax adhesions to the descending colon and ureters, neo-
vascularization and adherence to the bladder without
multiorgan resection and with macroscopic free margins
(Fig. 3). Complete resection of the tumor was performed.
The patient had a satisfactory evolution and was dis-
charged 48 h postsurgery without adjuvant treatment. The
final histopathological report showed undifferentiated
liposarcoma of the retroperitoneum (80 × 50 × 35 cm)
weighing 18 kg.
The patient is being followed-up every 3 months. At 6
months post-surgery, a new CT scan was done and there
was no evidence of disease (Fig. 4). Currently, at 14
months of follow-up, the patient is asymptomatic and dis-
ease free.
Discussion
Liposarcoma is the most frequent histological type of ret-
roperitoneal sarcoma, corresponding to 41% of these
tumors [4,5]. It has been reported that 20% of the tumors
are > 10 cm at the time of diagnosis [3]; however, few
cases of retroperitoneal liposarcomas exist that can be
considered as giant [4,6-9]. The case we present may be
considered among the largest tumors reported for this his-
tology. Clinically, these tumors tend to present with dif-
fuse abdominal pain accompanied by anorexia and
weight loss and increase in abdominal girth. The most
characteristic sign is a painless abdominal mass detected
in ~78% of the cases. Abdominal symptomatology is due
to compression of the organs, similar to that reported with
the present case [3,4]. It is clear that our patient presented
all the signs and symptoms specific for these tumors due
to the size of the abdominal mass.
Well-differentiated sclerosing liposarcoma Figure 2
Well-differentiated sclerosing liposarcoma.World Journal of Surgical Oncology 2008, 6:115 http://www.wjso.com/content/6/1/115
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The tumor was initially considered nonresectable and,
therefore, systemic treatment with chemotherapy was
decided upon, with the goal of reducing tumor load. Var-
ious chemotherapy regimens have been described based
on mesna, doxorubicin, ifosfamide, dacarbazine and pacl-
itaxel. However, their use is limited for recurrent meta-
static disease or palliation. Survival benefits have not been
demonstrated [10]. Due to the large tumor load and prob-
able multiorgan involvement, we initially considered pal-
liative treatment for our patient. Because the patient did
not demonstrate any beneficial effects from chemother-
apy, the joint decision of the hospital committee, along
with the patient, was to perform surgery. Complete resec-
tion of the tumor was performed. We are in agreement
with Patrik et al. [6] who demonstrated that in liposarco-
mas > 10 cm, complete resection can be carried out in up
to 70% of cases; however, in up to 50% of these cases,
multiorgan resection is necessary in order to reach this
goal [2]. The most frequent organ resected is the kidney
(30%). In the case we report here, even with the large size
of the tumor, organ resection was not necessary, because
there was no infiltration to neighboring structures, only
lax adhesions allowing adequate dissection of the tumor,
as shown in Fig. 3.
Radiotherapy (RT) was not considered in this case for two
principal reasons: the first was due to the large tumor load
and no demonstrable reduction in tumor size and, sec-
ond, because of the probable gastrointestinal morbidity
associated with such an extensive field as in this case. With
regard to RT as complementary treatment, there is agree-
ment for its palliative use in non-operable tumors or in
cases of incomplete resection [7,8]. Although mesodermic
tumors are radioresistant, liposarcoma is more radiosensi-
tive [6]. Although it has been noted that RT may increase
survival and disease-free interval [3,7,8], other authors
reported that this treatment has not demonstrated long-
term improvement in survival or specific disease in cases
Retroperitoneal tumor (80 × 60 cm), weighing 18 kg Figure 3
Retroperitoneal tumor (80 × 60 cm), weighing 18 kg. Complete resection.World Journal of Surgical Oncology 2008, 6:115 http://www.wjso.com/content/6/1/115
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of complete macroscopic resections [6,8]. This occurs
despite using intraoperative RT with the goal of increasing
efficacy of the local dose with 50–60 Gy [7] and of mini-
mizing toxicity to adjacent organs. In our case, because we
were dealing with a well-differentiated primary liposar-
coma that allowed complete resection, 5-year survival of
75–100% [9,11] has been described. Local failure occurs
within 5 to 10 years after resection in up to 90% of the
cases related to size of tumor, inability to achieve free mar-
gins and limitations of adjuvant treatment such as chem-
otherapy or RT [3,4]. We cannot compare these data with
our report because our patient is disease free at 14 months
of follow-up.
Conclusion
Retroperitoneal liposarcomas are a unique situation and
require a more aggressive surgical approach including,
when necessary, multiorgan resection or multiple resec-
tions with recurrences. In accordance with the ability of
the patient to tolerate the procedure, surgery is suggested
CT scan Figure 4
CT scan. No evidence of tumor activity is demonstrated. Localization of intraabdominal organs is adequate.Publish with BioMed Central    and   every 
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to evaluate tumor resectability, taking into consideration
prolonged survival. After tumor removal, palliation of
symptoms will be accomplished.
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